

RUSH: Journal of Oral and Maxillofacial Surgery article <# 52799> for proofing by Hita Iglesias

=====

Dear Author,

The proof of your article, to be published by Elsevier in Journal of Oral and Maxillofacial Surgery, is available as a "PDF" file at the following URL:

<http://rapidproof.cadmus.com/RapidProof/retrieval/index.jsp>

Login: your e-mail address

Password: ----

The site contains 1 file. You will need to have Adobe Acrobat Reader software to read these files. This is free software and is available for user download at: <http://www.adobe.com/products/acrobat/readstep.html>

After accessing the PDF file, please:

- 1) Carefully proofread the entire article, including any tables, equations, figure legends and references.
- 2) Ensure that your affiliations and address are correct and complete.
- 3) Check that any Greek letter, especially "mu", has translated correctly;
- 4) Verify all scientific notations, drug dosages, and names and locations of manufacturers;
- 5) Be sure permission has been procured for any reprinted material.
- 6) Answer all author queries completely. They are listed on the last page of the proof;

You may choose to list the corrections (including the replies to any queries) in an e-mail and return to me using the "reply" button. Using this option, please refer to the line numbers on the proof. If, for any reason, this is not possible, mark the corrections and any other comments (including replies to questions) on a printout of the PDF file and fax this to Laura Dinkins-White(215-239-3388) or mail to the address given below.

Do not attempt to edit the PDF file (including adding <post-it> type notes).

Within 48 hours, please return the following to the address given below:

- 1) Corrected PDF set of page proofs
- 2) Print quality hard copy figures for corrections if necessary (we CANNOT accept figures on disk at this stage). If your article contains color illustrations and you would like to receive proofs of these illustrations, please contact us within 48 hours.

If you have any problems or questions, please contact me. **PLEASE ALWAYS INCLUDE YOUR ARTICLE NUMBER** (located in the subject line of this e-mail) **WITH ALL CORRESPONDENCE.**

Sincerely,

Laura Dinkins-White
Senior Journal Manager
Elsevier Science
1600 John F.Kennedy Blvd.
Philadelphia, PA 19103-2899
Phone: 215-239-3375
Fax: 215-239-3388
la.white@elsevier.com

Effectiveness of Chlorhexidine Gel Versus Chlorhexidine Rinse in Reducing Alveolar Osteitis in Mandibular Third Molar Surgery

Pilar Hita Iglesias, DDS, PhD, Daniel Torres Lagares, DDS, PhD,† Rafael Flores Ruiz, DDS,‡ Natale Magallanes Abad, DDS,§ Marta Basallote Gonzalez, DDS,|| and Jose Luis Gutierrez Perez, MD, DDS¶*

Purpose: Chlorhexidine is an antimicrobial agent used in the prevention of postextraction alveolar osteitis, tooth decay and periodontal diseases.

There are various forms of chlorhexidine application. The most extensively studied is one that uses the rinse as the form of application.

Recently, a bioadhesive gel form has become available. Its main advantage is that it prolongs the bioavailability of chlorhexidine in the application area.

The purpose of this study was to compare the effectiveness of chlorhexidine gel versus a chlorhexidine rinse in reducing postoperative alveolar osteitis after the extraction of mandibular third molars.

Materials and Methods: The experimental or gel group (n = 41) applied the bioadhesive 0.2% chlorhexidine gel to the wound during the first postoperative week and a control or rinse group (n = 32) used a 0.12% chlorhexidine rinse during the first week postextraction.

Results: We observed a 70% decrease in postoperative alveolar osteitis in the gel group (P = .040). The rinse group had 25% incidence postoperative alveolar osteitis, while the gel group had 7.5%.

Conclusions: It was concluded that the topical application of bioadhesive chlorhexidine gel to the surgical wound during the postoperative week may decrease the incidence of alveolar osteitis after extraction of the mandibular third molars.

© 2007 American Association of Oral and Maxillofacial Surgeons
J Oral Maxillofac Surg xx:xxx, 2007

Alveolar osteitis (AO) is a postextraction complication that was first defined by Crawford¹ in 1896. Throughout the years, various synonyms for AO have been used, such as alveolitis sicca dolorosa (dry socket), alveolgia, osteomyelitis or fibrinolytic osteitis, pos-

textraction osteomyelitis syndrome, fibrinolytic alveolitis, and localized alveolar osteitis.²⁻⁵

The most recent of these terms was provided by Blum, who defines AO as a postoperative pain in and around the dental alveolus, which increases in severity at some stage between the first and third day postextraction, accompanied by a partial or total disintegration of the intra-alveolar blood clot, and which may be accompanied by halitosis.⁶

The frequency of AO appearance ranges from 1% to 70%.^{6,7-12} The average rate of AO for all dental extractions is 3% to 4%, according to various authors.^{7,13,14} The highest incidence generally occurs following the extraction of impacted third molars. In these cases, it may occur in 20% to 30% of these extractions,¹⁵⁻¹⁹ ie, 10 times more than for other dental extractions.⁶

Epidemiological studies linked to AO have identified various risk factors: difficulty of extraction, surgeon's inexperience, use of oral contraceptives,

*Department of Oral and Maxillofacial Surgery, University of Michigan, Ann Arbor, MI.

†Assistant Professor, Oral Surgery.

‡Master of Oral Surgery.

§Master of Oral Surgery.

||Master of Oral Surgery.

¶Professor and Chairman.

Address correspondence and reprint requests to Dr Iglesias: University of Michigan, Oral and Maxillofacial Surgery, 1500 Medical Center Dr., Ann Arbor, MI 48103; e-mail: pilarh@umich.edu

© 2007 American Association of Oral and Maxillofacial Surgeons

0278-2391/07/xx0x0\$32.00/0

doi:10.1016/j.joms.2007.06.641

advanced age, female gender, smoking, immunosuppression, and surgical trauma.^{18,20}

AO causes increased psychological harm to the patient and the health professionals, because the painful symptoms which accompany this pathology are extremely uncomfortable for the patient.²¹

Chlorhexidine (CHX) is a biguanide antiseptic agent that has been proven effective in the prevention of AO in the form of a mouth rinse and bioadhesive gel. The method of administration of this gel has the main advantage of providing a greater bioavailability in the application area, and therefore the medication has a more prolonged release.^{12,21} The objective of this study is to compare the effectiveness of these two forms of CHX (0.2% bioadhesive gel and 0.12% rinse) in the prevention of postoperative AO after the extraction of retained third molars, by means of topical application to the wound during the 7 days after the intervention.

Materials and Methods

This clinical study was a randomized, prospective clinical trial with parallel groups in a single center. It was carried out in the Faculty of Odontology at the University of Seville and in the Oral and Maxillofacial Surgery Service of the Virgen de Rocio University Hospitals, Seville. The study involved the treatment of 73 patients of both genders, between the ages of 18 and 60 years old, from June 2005 to November 2005. These patients presented with a mandibular third molar with a difficulty index ranging between 4 and 7, inclusive, according to the Koerner scale.²² The degree of difficulty was rated by a single investigator who performed all preoperative patient selection. Extraction of the molar was required. The patients could not take any type of antibiotic or analgesic in the 4 days preceding the procedure. Exclusion criteria included the following: nonfulfillment of 1 or all of the inclusion criteria, patients with any other disease which would contraindicate oral surgery, patients with AIDS or any type of immunosuppression, pregnant or lactating women, patients allergic to chlorhexidine, articaine, paracetamol or ibuprofen, patients in whom the administration of epinephrine is contraindicated, patients who required the simultaneous extraction of two wisdom teeth, patients who presented with a jawbone associated pathology, patients in whom the extraction of the retained wisdom tooth lasted for more than 30 minutes and noncooperative patients (psychic-motor dysfunction and behavior disorders).

All of the patients in the study gave their informed consent, and were covered by public liability insurance. The study was approved by the Ethics Committee of the University of Seville and followed the principles of the Helsinki Declaration.

Two pharmaceutical forms of CHX were studied: 0.2% bioadhesive gel and 0.12% mouth rinse (Laboratorios Lácer SA, Barcelona, Spain). The aim was to compare the decrease in postoperative AO incidence among the group of patients who received application of CHX bioadhesive gel, and those who received CHX rinse, both in the topical form, during the postoperative period after surgery to extract the mandibular third molar.

The patients underwent intervention of the inferior alveolar nerve and buccal nerve under local anesthesia (articaine 4% epinephrine, Laboratorios Inibsa, Barcelona, Spain). A bayonet incision was performed in order to gain access to the wisdom tooth, carrying out osteotomy in all cases and dental sectioning when necessary. Once the tooth had been extracted, the alveolus was cleaned, the bone edges were smoothed, and bioadhesive 0.2% chlorhexidine gel was applied inside the alveolus. Finally, the wound was sutured with simple 4/0 silk stitches.

The patients were randomly classified into 2 groups by means of a simple allocation using a computer program: the gel group and the rinse group, according to the pharmaceutical form of CHX used during the postoperative period. Having carried out the procedure, the envelope corresponding to the patient code was opened, and this indicated the group to which the patient had been assigned. By way of postoperative treatment, the patients took 600 mg ibuprofen (1 tablet every 8 hours) and 500 mg of 14.05 mg paracetamol codeine (1 tablet every 8 hours; Cod-efferalgan®, Bristol-Myers-Squibb, Madrid, Spain).

The patients in the gel group continued topical treatment with bioadhesive CHX gel, applied to the surgical wound twice a day (morning and night time) during the first postoperative week, beginning on the same day as the intervention. The patients in the rinse group continued topical treatment with CHX mouthwash, used twice a day (morning and night time) during the postoperative week, beginning on the same day as the intervention.

The independent variable was the application of CHX bioadhesive gel or CHX rinse during the postoperative period. The main dependent variable was the appearance of postoperative AO according to Blum's standardized criteria.

Subjects were evaluated on the third and seventh postoperative day. Diagnosis of AO was considered positive when patients presented with postoperative pain in and around the dental alveolus, that had increased in severity sometime between the first and third postoperative day, and was accompanied by partial or total loss of the intra-alveolar blood clot. In addition, the link between the appearance of postoperative AO and the risk variables described in the

literature were analyzed: age, gender, smoking, oral contraceptives, and degree of difficulty of extraction.

All clinical assessment was carried by a single blind investigator, trained by the directors of this study in previous studies sharing the same AO criteria. All study subjects reported using the medication prescribed to them. Compliance assessment was achieved by intention-to-treat analysis. Tolerance to the treatment, defined as the frequency that patients developed 1 or more adverse effects was assessed on a verbal score of 1 (maximum tolerance) to 5 (minimum tolerance or maximum intolerance) during the third and seventh postoperative day. The χ^2 test was applied for the comparison of the proportions between the 2 groups (gel and rinse), and Student *t* test for the comparison of the mean values in quantitative variables.

Results

A total of 73 patients underwent intervention (73 mandibular third molars). There were 41 patients in the gel group and 32 patients in the rinse group. The progress of a total of 70 were followed until the end of the study, because 2 patients from the gel group and 1 from the rinse group did not complete the study. The average age was 29 years old (ranging from 18 to 59). Fifty-four patients were female and 19 were male. Eight women were taking oral contraceptives. Twenty-nine patients were smokers (16 females and 10 males). Details of both groups regarding age, gender, smoking habits, use of oral contraceptives, and degree of difficulty are displayed in Table 1 (significant statistical differences were not found between the two groups).

In the gel group, 7.5% of AO incidence was found, while in the mouthwash group, there was 25%; the difference was statistically significant, *P* = .040 for the χ^2 test (Table 1). None of the patients displayed adverse effects to the treatment, and there was adequate tolerance in both groups.

Discussion

Currently, there are two main etiopathogenic theories about AO: Birn's fibrinolytic theory and the bacterial theory.^{3,15-19,21} With respect to these etiopathogenic theories, the prevalence of one theory over the other has not been generally accepted, as there is no conclusive data to definitively reject or accept one of the two. The origin of AO probably lies in an interactive mix of both theories.

Epidemiological studies related to AO have identified various risk factors in the development of AO, mainly: difficulty of extraction, surgeon's inexperience, use of oral contraceptives, advanced age, fe-

Table 1. DATA ON DEMOGRAPHICS, DIFFICULTY INDEX OF EXTRACTION, ALVEOLAR OSTEITIS INCIDENCE, AND TOLERANCE OF THE TREATMENT CARRIED OUT

	Gel Group (n = 41 Patients; 56.2%)	Rinse Group (n = 32 Patients 43.8%)
Age, mean (yr)	28	26
Age, range (yr)	59-18	49-18
Gender		
Female, n (%)	27 (65.8)	27 (84.4)
Male, n (%)	14 (34.2)	5 (15.6)
Smoker		
Yes, n (%)	16 (39.9)	10 (31.3)
No, n (%)	25 (60.1)	22 (68.7)
Contraceptives		
Yes	6 (14.6)	2 (6.3)
No	35 (85.4)	30 (93.7)
Difficulty index of extractions*		
4	6 (14.7)	5 (15.6)
5	20 (48.7)	16 (50)
6	14 (34.1)	11 (34.4)
7	1 (2.5)	0
Tolerance†		
1	28 (68.3)	25 (79.1)
2	6 (16.6)	4 (14.5)
3	3 (8.3)	1 (3.2)
4	2 (6.8)	1 (3.2)
5	0	0
Alveolar osteitis‡		
Yes	3 (7.5)	8 (25)
No	37 (92.5)	24 (75)

Data are n (%) except where noted.

*●●●

†Verbal scale from 1 meaning totally tolerable, to 5 meaning totally intolerable.

‡Student *t* test, *P* = .040.

Iglesias et al. Chlorhexidine Gel vs Rinse and Osteitis. J Oral Maxillofac Surg 2007.

male gender, smoking, immunosuppression, and surgical trauma.^{18,22}

The preventative measures taken in the therapeutic management of AO are summarized as follows: washing with saline solution, eugenol dressings to provide relief, antifibrinolytic agents, antibiotics, and antiseptic agents. These last 2 measures are, probably, those that have had the most success in the prevention of AO.^{20,23,24,29} Antibiotics are more expensive, may create resistance and their efficiency in the prevention of AO has been questioned by several authors.¹⁹

The contributions which support the validity of CHX in the control of bacterial plaque²⁵ and the relation between oral hygiene and the prevention of alveolitis sicca²⁶ have been numerous to date.

CHX has been shown to be a good preventative agent of AO. Various application protocols have been studied, both in mouth rinse and in the postoperative intra-alveolar application of bioadhesive gel, although

there are no studies which simultaneously compare the effectiveness of CHX bioadhesive gel with CHX rinse following the extraction of retained mandibular third molars.

In a recent meta-analysis by Caso et al²¹ on the use of CHX on impacted third molars in the postoperative period, the authors concluded that the use of CHX mouth rinse from the day of intervention and during the postoperative period produce a decrease in AO incidence. The minimum postoperative period of time during which mouthwash should be applied could not be determined in this study.

Berwick and Lessin¹⁷ did not discover differences in AO incidence in the 2 study groups (CHX 0.12% and cetylpyridinium 0.05%). Delilbasi et al²⁷ found similar percentages of AO, using 0.2% CHX mouth rinse and saline solution. Ragno and Szkutnik¹⁶ discovered a 17.5% decrease in the group that used 0.2% CHX mouth rinse after the extraction of retained third molars compared with 36% of AO in the control group (placebo).

Larsen²⁸ found 16% of AO in the control group (placebo) compared with 8% in the experimental group (0.12% CHX mouth rinse during the pre and postoperative weeks). Other authors have found a 50% decrease of AO incidence using 0.12% CHX mouth rinse. Torres et al²⁹ discovered an 11% decrease of AO in the experimental group (intra-alveolar bioadhesive 0.2% CHX gel) after the extraction of retained mandibular third molars, compared with 30% in the experimental group (intra-alveolar medication versus placebo).

The only study that we have found which compares various proportions of chlorhexidine did not show significant differences between the 0.1% and 0.2% CHX groups. There was a significant improvement between both chlorhexidine groups and the control group.²⁵ Although the concentration of chlorhexidine was different in the gel group and in the mouthwash group, previous data supports the comparability of both groups.

The number of patients in this study is sufficient to assess the main variable: appearance or absence of AO postextraction. In other studies, this number ranges between 20 and 67 per group.^{15,17,18,25,27} The average age of the patients was higher than that obtained by other authors. With respect to the proportion of males/females, there are studies such as those by Torres et al²⁹ and Hermesch et al,³⁰ which coincide with our data, while other authors had a similar proportion of males/females³⁰ in their studies. With respect to the use of oral contraceptives (14%), we obtained similar results to those of Torres et al.²⁹ In other studies such as those by Larsen²⁸ and Hermesch et al,³⁰ the results showed percentages of 53% and 32% respectively for women who were taking the oral

contraceptives, while in the study by Bonine,³¹ this value did not surpass 6%.

The percentage of patients who smoked, was higher than in studies by other authors such as Torres et al²⁹ (25% of smokers in their sample) and Larsen²⁸ (28.16% of smokers). Nevertheless, these percentages are within the limits found in other literature (16.3%, 15.12% and 25.42%).^{27,30,31} We have not found significant statistical differences in AO incidence in groups of smokers and nonsmokers, nor have we found significant differences between patients who take contraceptives and those who do not.

In the experimental group (gel), we found a statistically significant decrease (70%, $P = .05$) in the incidence of postoperative AO compared with the mouthwash group. These results may be explained by the bioadhesive properties of the gel, which prolong the release of CHX at the application site. No adverse effect was recorded in the patients treated, as referred to in other similar studies.³¹

The results of this clinical study show that the application of bioadhesive 0.2% CHX gel to the postoperative wound after the extraction of retained mandibular third molars decreases AO incidence compared with the application of 0.12% CHX mouthwash under similar circumstances.

Acknowledgments

The authors thank Laboratorios Lacer Barcelona España, for the donation of chlorhexidine samples used in this study.

References

1. Crawford JY: Dry socket. *Dent Cosmos* 38:929, 1986
2. Swanson AE: Prevention of dry socket: An overview. *Oral Surg Oral Med Oral Pathol* 70:131, 1990
3. Swanson AE: A double-blind study on effectiveness of tetracycline in reducing the incidence of fibrinolytic alveolitis. *J Oral Maxillofac Surg* 47:165, 1989
4. Moore JW, Brekke JH: Foreign body giant cell reaction related to placement of tetracycline-treated polylactic acid: Reported of 18 cases. *J Oral Maxillofac Surg* 48:808, 1990
5. Trieger N, Schlagel GD: Preventing dry socket. A simple procedure that works. *J Am Dent Assoc* 2:67, 1991
6. Blum IR: Contemporary views on dry socket (alveolar osteitis): A clinical appraisal of standardization, aetiopathogenesis and management: A critical review. *Int J Oral Maxillofac Surg* 31:309, 2002
7. García Murcia MJ, Peñarrocha Diago M: Alveolitis seca: Revisión de la literatura y metaanálisis. *Rev Actual Odontostomatol Esp* 44:25, 1994
8. Barclay JK: Metronidazole and dry socket: Prophylactic use in mandibular third molar removal complicated by non-acute pericoronitis. *N Z Dent J* 83:71, 1987
9. Fridrich KL, Olson RA: Alveolar osteitis following surgical removal of mandibular third molars. *Anesth Prog* 37:32, 1990
10. Rozanis J, Schofield ID, Warren BA: Is dry socket preventable? *Dent J* 43:233, 1977
11. Schow SR: Evaluation of postoperative localized osteitis in mandibular third molar surgery. *Oral Surg Oral Med Oral Pathol* 38:352, 1974
12. Ariza E, González J, Boneu F, Hueto JA, Raspall G: Incidencia de la alveolitis seca, tras la exodoncia quirúrgica de terceros mo-

172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227

228	lares mandibulares en nuestra Unidad de Cirugía Oral. Rev Esp	with patients using oral contraceptives. Am J Obstet Gynecol	228
229	Cir Oral Maxillofac 21:214, 1999	127:518, 1977	229
230	13. Rood JP, Murgatroyd J: Metronidazole in the prevention of "dry	24. Sweet JB, Butler DP: Predisposing and operative factors: Effect	230
231	socket." Br J Oral Surg 17:62, 1979	on the incidence of localized osteitis in mandibular third-molar	231
232	14. Jaafar N, Nor GM: The prevalence of post-extraction complica-	surgery. Oral Surg Oral Med Oral Pathol 46:206, 1978	232
233	tions in an outpatient dental clinic in Kuala Lumpur Malaysia: A	25. Fotos PG, Koorbusch GF, Sarasin DS, Kilt RJ: Evaluation of	233
234	retrospective survey. Singapore Dent J 23:24, 2000	intra-alveolar chlorhexidine dressings alter removal of im-	234
235	15. Larsen PE: The effect of a chlorhexidine rinse on the incidence	pacted mandibular third molars. Oral Surg Oral Med Oral	235
236	of alveolar osteitis following the surgical removal of impacted	Pathol 73:383, 1992	236
237	mandibular third molar. J Oral Maxillofac Surg 49:932, 1991	26. Tjernberg A: Influence of oral hygiene measures on the devel-	237
238	16. Ragno JR Jr, Szkutnik AJ: Evaluation of 0.12% chlorhexidine	opment of alveolitis sicca dolorosa after surgical removal of	238
239	rinse on the prevention of alveolar osteitis. Oral Surg Oral Med	mandibular third molar. Int J Oral Surg 8:430, 1979	239
240	Oral Pathol 72:524, 1991	27. Delilbasi C, Saracoglu U, Keskin A: Effects of 0.2% chlorhexi-	240
241	17. Berwick JE, Lessin ME: Effects of a chlorhexidine gluconate	dine gluconate and amoxicillin plus clavulanic acid on the	241
242	oral rinse on the incidence of alveolar osteitis in mandibular	prevention of alveolar osteitis following mandibular third mol-	242
243	third molar surgery. J Oral Maxillofac Surg 48:444, 1990	ar extractions. Oral Surg Oral Med Oral Pathol Oral Radiol	243
244	18. Larsen PE: Alveolar osteitis after surgical removal of impacted	Endod 94:301, 2002	244
245	mandibular third molars. Identification of the patient at risk.	28. Larsen PE: Use of chlorhexidine to prevent alveolar osteitis.	245
246	Oral Surg Oral Med Oral Pathol 73:393, 1992	J Oral Maxillofac Surg 48:1244, 1990	246
247	19. Ritzau M, Hillerup S, Branbjerg PE, Ersbol BK: Does metroni-	29. Torres D, Gutiérrez JL, Infante P, García-Calderón M, Romero	247
248	dazole prevent alveolitis sicca dolorosa? A double-blind, place-	MM, Serrera-Figallo MA: Randomized, double-blind study on	248
249	bo-controlled clinical study. J Oral Maxillofac Surg 21:299,	effectiveness of intra-alveolar chlorhexidine gel in reducing the	249
250	1992	incidence of alveolar osteitis in mandibular third molar surgery.	250
251	20. Bloomer CR: Alveolar osteitis prevention by immediate place-	Int J Oral Maxillofac Surg 35:348, 2006	251
252	ment of medicated packing. Oral Surg Oral Med Oral Pathol	30. Hermes CB, Hilton TJ, Biesbrock AR, et al: Perioperative use	252
253	Oral Radiol Endod 90:282, 2000	of 0.12% chlorhexidine gluconate for the prevention of alveo-	253
254	21. Caso A, Hung LK, Beirne OR: Prevention of alveolar osteitis	lar osteitis. Efficacy and risk factor analysis. Oral Surg Oral Med	254
255	with chlorhexidine: A meta-analytic review. Oral Surg Oral Med	Oral Pathol Oral Radiol Endod 85:381, 1998	255
256	Oral Pathol Oral Radiol Endod 99:155, 2005	31. Bonine FL: Effect of chlorhexidine rinse on the incidence of	256
257	22. Koerner KR: The removal of impacted third molars. Principles	dry socket in impacted mandibular third molar extraction	257
258	and procedures. Dent Clin North Am 38:255, 1994	sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod	258
259	23. Sweet JB, Butler DP: Increased incidence of postoperative	79:154, 1995	259
260	localized osteitis in mandibular third molar surgery associated		260
261			261
262			262
263			263
264			264
265			265
266			266
267			267
268			268
269			269
270			270
271			271
272			272
273			273
274			274
275			275
276			276
277			277
278			278
279			279
280			280
281			281
282			282
283			283

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

1

AQ9— Please confirm 68.7% is correct for non-smoking rinse group.

AQ10— For Tolerance, and Alveolar osteitis, please add comment in footnote as to why the number of patients in the gel group do not add to 41, and for Tolerance, rinse group, why the number of patients does not add to 32. Please check that percentages are correct for these categories.

AQ11— Please add to * footnote: Explanation of the scale used for difficulty index of extractions. Please note “number of teeth” was removed from heading; if needed, please clarify meaning of the phrase (eg, number (quantity) of teeth extracted, number of the tooth that was extracted, order in which the teeth were removed, or otherwise).

AQ1— Please approve or modify short title for running head (must be < 45 characters, including spaces).

AQ2— Please provide complete affiliation information for each author: position (eg, Professor), Department(s), institutional affiliation, and location (city, state, and country if not USA).

AQ3— Structured abstract headings are required, per journal style, and have thus been added. Please approve or modify placement.

AQ4— Date of publication for Crawford in reference list is 1986; is 1896 meant here?

AQ5— Please confirm AO meant here.

AQ6— ‘Conclusion’ is never allowed as a heading, per journal style, and has thus been deleted.

AQ7— Unable to verify journal on PubMed, or article with this title by this author; please confirm it is correct.

AQ8— Unable to verify reference on PubMed, using search of journal and first author; please confirm it is correct.
